推薦產品
等級
pharmaceutical primary standard
API 家族
pioglitazone
製造商／商標名
USP
應用
pharmaceutical (small molecule)
格式
neat
儲存溫度
2-8°C
SMILES 字串
Cl.CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1
InChI
1S/C19H20N2O3S.ClH/c1-2-13-3-6-15(20-12-13)9-10-24-16-7-4-14(5-8-16)11-17-18(22)21-19(23)25-17;/h3-8,12,17H,2,9-11H2,1H3,(H,21,22,23);1H
InChI 密鑰
GHUUBYQTCDQWRA-UHFFFAOYSA-N
基因資訊
human ... PPARG(5468)
尋找類似的產品？ 前往 產品比較指南
一般說明
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
應用
Pioglitazone hydrochloride USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
- Pioglitazone and Metformin Hydrochloride Tablets
- Pioglitazone Tablets
- Pioglitazone and Glimepiride Tablets
生化／生理作用
盐酸吡格列酮是一种PPARγ激动剂和噻唑烷二酮（TZD）抗糖尿病药物。吡格列酮是一种核受体过氧化物酶体增殖物激活受体γ（PPAR-γ）的选择性激动剂，并在较小程度上是PPAR-α。
分析報告
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
其他說明
Sales restrictions may apply.
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
分析證明 (COA)
輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號，寫有 ‘Lot’或‘Batch’.。
The use of oral pioglitazone in the treatment of lichen planopilaris.
Natasha Atanaskova Mesinkovska et al.
Journal of the American Academy of Dermatology, 72(2), 355-356 (2015-01-17)
Chin-Hsiao Tseng
Metabolism: clinical and experimental, 63(8), 1049-1055 (2014-06-04)
To investigate whether pioglitazone treatment of patients with type 2 diabetes mellitus was associated with an increased risk of kidney cancer. The reimbursement databases of all Taiwanese patients with type 2 diabetes who received oral anti-diabetic agents or insulin from
W Xu et al.
Journal of internal medicine, 277(1), 137-150 (2014-07-22)
Progressive β-cell dysfunction hinders the maintenance of glycaemic control in type 2 diabetes, but comparative data on β-cell-protective therapies are lacking in the early stage of type 2 diabetes. Here we evaluated the comparative glycaemic efficacy and impact on β-cell
Zhan Shi et al.
Pakistan journal of pharmaceutical sciences, 27(3), 537-539 (2014-05-09)
Raw Radix Rehmanniae (RRR) is a frequently used traditional Chinese medicine in the treatment of diabetes mellitus according to the statistics on all of the anti-diabetic formulas recorded in New National Traditional Chinese Medicine. Pioglitazone and RRR may be co-administrated
Catherine M Viscoli et al.
American heart journal, 168(6), 823-829 (2014-12-03)
Recurrent vascular events remain a major source of morbidity and mortality after stroke or transient ischemic attack (TIA). The IRIS Trial is evaluating an approach to secondary prevention based on the established association between insulin resistance and increased risk for
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務